Bioreactor-Technology and Equipment

Cell (or stem cell) therapy, as a new form of treatment

Bioreactor-Technology and Equipment

stemcell-banner

Regenerative Medicine would provide solutions for unmet needs and revolutionize clinical therapies and treatment.

Cell (or stem cell) therapy, as a new form of treatment, is a rapidly growing industry that has already exceeded the value of $1bn per year.The next phase of growth toward a multibillion-dollar global industry will depend on the bio-manufacturing innovation to meet growing market demands, and providing products at affordable costs. Both autologous and allogeneic treatment require ex vivo cell expansion after cell isolation from tissues collected from patients and/or donors, quality control, banking of cells after scale up/down of cell products and transportation of cell products safely to the bedside. At Oxford MEStar, we are currently working on the following areas associated with the stem cell bio-processing engineering.

If you are interested in our services or wish to explore collaborative opportunities, please contact us.


Bioreactor system for cell/stem cell expansion

Stem cell expansion is one of the core steps in the manufacturing of cell therapy products. The cell/stem cell expansion team at Oxford MEStar is developing an automated bioreactor system that will be based on culture techniques developed by the company’s cell culture experts. The bioreactor will be capable of producing large number of cells required for clinically effective doses of cell therapies; the cells will also be produced at a high density, reducing the need for any downstream concentration of the cultured cell product. The bioreactor will utilise Oxford MEStar’s expertise in developing fully automated systems; it will be made to operate with minimum human intervention, and it will be capable of monitoring and adjusting important cell culture parameters throughout the culture period. The design will minimise the risk of contamination of the cell culture, whilst optimising the number of disposable and reusable parts to balance capital and operational costs. The bioreactor will be scalable; the goal of large scale production has been considered from the beginning, resulting in incorporation of elements that will efficiently use all of the resources available.

If you are interested in our services or wish to explore collaborative opportunities, please contact us.


Automated natural tissue decellularisation system

A speciality of Oxford MEStar is our provision of bespoke R&D decellularisation systems, which are used for the automated scale up and production of natural tissue decellularised scaffolds. The system is designed to standardise and automatically conduct procedures required by regulation, including temperature control, buffer change, and waste disposal. The systems consist of decellularisation bioreactor systems: where natural tissue decellularisation processes are carried out in either stainless steel bioreactors, or in single-use-units with supports from pumping systems, mechanical movements, sensors, and monitoring systems. All parameters can be programmably controlled under desired conditions.

If you are interested in our services or wish to explore collaborative opportunities, please contact us.